title: Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
abstract: BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL. Furthermore, ALL therapy is associated with much worse responses to TKIs than those observed in CML. The identification of additional pathways that mediate BCR-ABL leukemogenesis is indeed mandatory to achieve synthetic lethality together with TKI. Here, we review the role of BCR-ABL/protein kinase CK2 interaction in BCR-ABL leukemias, with potentially relevant implications for therapy.
authors: Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
authors: Alessandro
authors: A
authors: Morotti
authors: Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
authors: Giovanna
authors: G
authors: Carrà
authors: Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
authors: Cristina
authors: C
authors: Panuzzo
authors: Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
authors: Sabrina
authors: S
authors: Crivellaro
authors: Department of Oncology, University of Turin, 10043 Orbassano, Italy.
authors: Riccardo
authors: R
authors: Taulli
authors: Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
authors: Angelo
authors: A
authors: Guerrasio
authors: Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
authors: Giuseppe
authors: G
authors: Saglio